Skip Ribbon Commands
Skip to main content
Sign In

24994 NMO/AQP4-IgG Cell Binding Assay (NMOCS)

NMO/AQP4-IgG Cell Binding Assay (NMOCS)
Test Code: NMOESO
Synonyms/Keywords
AQP, AQP4, Aquaporin, Devic's Antibody, NMO (Neuromyelitis Optica), NMO-IgG, Optic Neuritis Antibody, Transverse Myelitis Antibody, Vision Loss Antibody
Useful For

Diagnosis of a neuromyelitis optica spectrum disorder (NMOSD).

Distinguishing NMOSD from multiple sclerosis early in the course of disease.

Specimen Requirements
Specimen Type Preferred Container/Tube Acceptable Container/Tube Specimen Volume Specimen Minimum Volume
(allows for 1 repeat)
Pediatric Minimum Volume
(no repeat)
Serum​ ​Red Top Tube (RTT) ​Serum Separator Tube (SST) ​1.0 mL ​0.5 mL
Specimen Stability Information
Specimen Type Temperature Time
Serum​ ​ ​ ​Ambient ​72 hours
Refrigerated (preferred) 28 days​
​Frozen ​28 days
Rejection Criteria
Gross Hemolysis
​ Gross Icterus
Performing Laboratory Information
Performing Location Day(s) Test Performed Analytical Time Methodology/Instrumentation
Mayo Medical Laboratories​​
 
Monday through Friday
3 days​
Cell-Binding Assay (CBA) Detects IgG Specific for AQP4 (M1 isoform) by IFA
Reference Lab
Test Information

Neuromyelitis optica (NMO), sometimes called Devic disease, is a severe, relapsing, autoimmune inflammatory, and demyelinating central nervous system disease that predominantly affects optic nerves and the spinal cord. The disorder is now recognized as a spectrum of autoimmunity targeting the astrocytic water channel aquaporin-4 (AQP4). NMO spectrum disorders (NMOSD) may involve the brain and brainstem with symptoms of encephalopathy (particularly in children). The initial symptoms may be bouts of intractable nausea and vomiting. Magnetic resonance imaging typically reveals large inflammatory spinal cord lesions involving 3 or more vertebral segments. During acute attacks, the cerebrospinal fluid contains inflammatory cells, but usually lacks evidence of intrathecal IgG synthesis. The clinical course is characterized by relapses of optic neuritis or transverse myelitis, or both.

Prior to introducing a serological biomarker for NMO, the disorder was thought to be confined exclusively to the optic nerves and spinal cord, that the clinical course was monophasic, and that NMO was a subset of multiple sclerosis (MS). The discovery of a highly specific disease marker for NMO, NMO-IgG/AQP4-IgG helped to define the full clinical spectrum of NMOSD and distinguish these disorders from MS.

Many patients with NMOSD are misdiagnosed as having MS. Importantly, the prognosis and optimal treatments for the 2 diseases differ. NMOSD typically has a worse natural history than MS, with frequent and early relapses. NMOSD attacks are often severe resulting in a rapid accumulation of disability (blindness and paraplegia). Within 5 years, 50% of patients lose functional vision in at least 1 eye or are unable to walk independently. Treatments for NMOSD include corticosteroids and plasmapheresis for acute attacks and mycophenolate mofetil, azathioprine, and rituximab for relapse prevention. Beta-interferon, a treatment promoted for MS, exacerbates NMOSD. Therefore, early diagnosis and initiation of NMO-appropriate immunosuppressant treatment is important to optimize the clinical outcome by preventing further attacks.

Reference Range Information
Performing Location Reference Range
Mayo Medical Laboratories​​
Negative
Interpretation
A positive value is consistent with a neuromyelitis optica spectrum disorder (NMOSD) and justifies initiation of appropriate immunosuppressive therapy at the earliest possible time. This allows early initiation and maintenance of optimal therapy. Recommend follow-up in 6 months if NMOSD is suspected. This autoantibody is not found in healthy subjects.  A negative result does not exclude a diagnosis of neuromyelitis optica spectrum disorder (NMOSD).
Outreach CPTs
CPT Modifier
(if needed)
Quantity Description Comments
​86255 ​1
Synonyms/Keywords
AQP, AQP4, Aquaporin, Devic's Antibody, NMO (Neuromyelitis Optica), NMO-IgG, Optic Neuritis Antibody, Transverse Myelitis Antibody, Vision Loss Antibody
Ordering Applications
Ordering Application Description
​Centricity ​NMO Evaluation (60796)
​Cerner ​None
If the ordering application you are looking for is not listed, contact your local laboratory for assistance.
Specimen Requirements
Specimen Type Preferred Container/Tube Acceptable Container/Tube Specimen Volume Specimen Minimum Volume
(allows for 1 repeat)
Pediatric Minimum Volume
(no repeat)
Serum​ ​Red Top Tube (RTT) ​Serum Separator Tube (SST) ​1.0 mL ​0.5 mL
Specimen Stability Information
Specimen Type Temperature Time
Serum​ ​ ​ ​Ambient ​72 hours
Refrigerated (preferred) 28 days​
​Frozen ​28 days
Rejection Criteria
Gross Hemolysis
​ Gross Icterus
Useful For

Diagnosis of a neuromyelitis optica spectrum disorder (NMOSD).

Distinguishing NMOSD from multiple sclerosis early in the course of disease.

Reference Range Information
Performing Location Reference Range
Mayo Medical Laboratories​​
Negative
Interpretation
A positive value is consistent with a neuromyelitis optica spectrum disorder (NMOSD) and justifies initiation of appropriate immunosuppressive therapy at the earliest possible time. This allows early initiation and maintenance of optimal therapy. Recommend follow-up in 6 months if NMOSD is suspected. This autoantibody is not found in healthy subjects.  A negative result does not exclude a diagnosis of neuromyelitis optica spectrum disorder (NMOSD).
For more information visit:
Performing Laboratory Information
Performing Location Day(s) Test Performed Analytical Time Methodology/Instrumentation
Mayo Medical Laboratories​​
 
Monday through Friday
3 days​
Cell-Binding Assay (CBA) Detects IgG Specific for AQP4 (M1 isoform) by IFA
Reference Lab
For billing questions, see Contacts
Outreach CPTs
CPT Modifier
(if needed)
Quantity Description Comments
​86255 ​1
For most current information refer to the Marshfield Laboratory online reference manual.